#chlamydia

April is STD Awareness Month.

An annual surveillance report on STIs and other blood-borne illnesses also found that new cases of hepatitis B are down among youths.

The news first broke in February about a man in Amsterdam who contracted non-drug-resistant HIV while apparently adhering well to PrEP.

The recommended twice-yearly STI screening would drive this effect, likely compensating for any excess sexual risk taking in PrEP users.

Rising gonorrhea among gay and bi men in particular is concerning given recent warnings about the emergence of drug-resistant strains.

This video is about disclosing HIV status on dating apps.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

Following a recent finding of a major drop in HIV diagnoses at the 56 Dean St. clinic, the decline in gonorrhea diagnoses is encouraging.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

It is unclear how going on Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) may have affected these rates.

However, might post-exposure prophylaxis (PEP) against STIs impact resistance to antibiotics among infections like gonorrhea?

A modeling study suggests that HIV meds’ effects on the immune response may partially explain the recent rise in syphilis in gay and bi men.

Men who have sex with men (MSM) account for most new cases of gonorrhea and syphilis.

The CDC’s first state-by state breakdown of rates of the STI among men who have sex with men reveals a heavy burden in the South.

The World Health Organization has recommended updated treatment protocols to combat drug-resistant gonorrhea, chlamydia and syphilis.

PrEP use and high STI rates are connected, but more research is needed to determine whether starting PrEP actually causes STI rates to rise.